Physician profile
Mari Rivera
NPI 1154550051
$2,229.31
in general payments reported to CMS, 2019-2025
14 companies · $462 in 2025
The $462 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $84.29 · 2021: $95.47 · 2022: $268 · 2023: $65.34 · 2024: $795 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.86 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $242.46 | 2025 | Tremfya |
| Novo Nordisk INC | $144.96 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $141.24 | 2024 | Voquezna |
| Regeneron Pharmaceuticals, INC. | $139.47 | 2022 | |
| Mallinckrodt Hospital Products INC. | $132.71 | 2024 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $129.30 | 2024 | Dupixent |
| Allergan, INC. | $125.00 | 2019 | |
| Celltrion USA INC. | $112.00 | 2025 | Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $95.47 | 2021 | |
| Boston Scientific Corporation | $73.22 | 2019-2023 | |
| Becton, Dickinson and Company | $71.11 | 2025 | Hemosphere |
| Mentor Worldwide LLC | $69.42 | 2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Lilly USA, LLC | $26.09 | 2024 | Zepbound, Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mari Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.